Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 2 selected

Type

Guidance programme 6 selected

Guidance programme

Showing 1 to 10 of 1495

TitleReference numberPublishedLast updated
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney diseaseTA1035
Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer (terminated appraisal)TA1032
Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumoursTA1034
Vamorolone for treating Duchenne muscular dystrophy in people 4 years and overTA1031
Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal)TA1028
Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal)TA1029
Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancerTA1030
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxabanTA697
Electrically stimulated intravesical therapy for interstitial cystitis or overactive bladder in adultsIPG799
Tebentafusp for treating advanced uveal melanomaTA1027

Results per page

  1. 10
  2. 25
  3. 50
  4. All